103 related articles for article (PubMed ID: 21152846)
1. Recent developments in naltrexone implants and depot injections for opiate abuse: the new kid on the block is approaching adulthood.
Brewer C; Streel E
Adicciones; 2010; 22(4):285-91. PubMed ID: 21152846
[TBL] [Abstract][Full Text] [Related]
2. Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels.
Foster J; Brewer C; Steele T
Addict Biol; 2003 Jun; 8(2):211-7. PubMed ID: 12850780
[TBL] [Abstract][Full Text] [Related]
3. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
[TBL] [Abstract][Full Text] [Related]
4. Naltrexone: a review of existing sustained drug delivery systems and emerging nano-based systems.
Goonoo N; Bhaw-Luximon A; Ujoodha R; Jhugroo A; Hulse GK; Jhurry D
J Control Release; 2014 Jun; 183():154-66. PubMed ID: 24704710
[TBL] [Abstract][Full Text] [Related]
5. [The use of different forms of naltrexone in the treatment of opioid dependence].
Krupitskiĭ EM; Zvartau EE; Blokhina EA; Woody G
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(11 Pt 2):66-72. PubMed ID: 22611701
[TBL] [Abstract][Full Text] [Related]
6. Injectable extended-release naltrexone for opioid dependence.
Woody GE; Metzger DS
Lancet; 2011 Aug; 378(9792):664-5; author reply 666. PubMed ID: 21856476
[No Abstract] [Full Text] [Related]
7. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
Krupitsky E; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Silverman BL
Addiction; 2013 Sep; 108(9):1628-37. PubMed ID: 23701526
[TBL] [Abstract][Full Text] [Related]
8. Naltrexone implants -- duration, tolerability and clinical usefulness. A pilot study.
Waal H; Frogopsahl G; Olsen L; Christophersen AS; Mørland J
Eur Addict Res; 2006; 12(3):138-44. PubMed ID: 16778434
[TBL] [Abstract][Full Text] [Related]
9. [Long-acting naltrexone--a new way out of opiate addiction?].
Stavseth LS; Kunøe N; Tanum L
Tidsskr Nor Laegeforen; 2013 Nov; 133(21):2231-2. PubMed ID: 24226324
[No Abstract] [Full Text] [Related]
10. Factors associated with using opiates while under extended-release naltrexone blockade: A descriptive pilot study.
Jarvis BP; DeFulio A; Long L; Holtyn AF; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
J Subst Abuse Treat; 2018 Feb; 85():56-60. PubMed ID: 28161142
[TBL] [Abstract][Full Text] [Related]
11. Intramuscular extended-release naltrexone: current evidence.
Gastfriend DR
Ann N Y Acad Sci; 2011 Jan; 1216():144-66. PubMed ID: 21272018
[TBL] [Abstract][Full Text] [Related]
12. Serum naltrexone and 6-beta-naltrexol levels from naltrexone implants can block very large amounts of heroin: a report of two cases.
Brewer C
Addict Biol; 2002 Jul; 7(3):321-3. PubMed ID: 12126492
[TBL] [Abstract][Full Text] [Related]
13. [Limited role of naltrexone in the treatment of opiate addiction].
van Brussel GH
Ned Tijdschr Geneeskd; 2001 Jul; 145(30):1452-6. PubMed ID: 11503313
[TBL] [Abstract][Full Text] [Related]
14. Examination of mortality rates in a retrospective cohort of patients treated with oral or implant naltrexone for problematic opiate use.
Kelty E; Hulse G
Addiction; 2012 Oct; 107(10):1817-24. PubMed ID: 22487087
[TBL] [Abstract][Full Text] [Related]
15. Favorable mortality profile of naltrexone implants for opiate addiction.
Reece AS
J Addict Dis; 2010 Jan; 29(1):30-50. PubMed ID: 20390697
[TBL] [Abstract][Full Text] [Related]
16. Long-acting depot formulations of naltrexone for heroin dependence: a review.
Krupitsky EM; Blokhina EA
Curr Opin Psychiatry; 2010 May; 23(3):210-4. PubMed ID: 20224403
[TBL] [Abstract][Full Text] [Related]
17. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.
Hulse GK; Morris N; Arnold-Reed D; Tait RJ
Arch Gen Psychiatry; 2009 Oct; 66(10):1108-15. PubMed ID: 19805701
[TBL] [Abstract][Full Text] [Related]
18. Maintenance treatment with depot opioid antagonists in subcutaneous implants: an alternative in the treatment of opioid dependence.
Carreño JE; Alvarez CE; Narciso GI; Bascarán MT; Díaz M; Bobes J
Addict Biol; 2003 Dec; 8(4):429-38. PubMed ID: 14690879
[TBL] [Abstract][Full Text] [Related]
19. Promise of extended-release naltrexone is a red herring.
Bart G
Lancet; 2011 Aug; 378(9792):663; author reply 663-4. PubMed ID: 21856474
[No Abstract] [Full Text] [Related]
20. A Phase 4, Pilot, Open-Label Study of VIVITROL® (Extended-Release Naltrexone XR-NTX) for Prisoners.
Gordon MS; Kinlock TW; Vocci FJ; Fitzgerald TT; Memisoglu A; Silverman B
J Subst Abuse Treat; 2015 Dec; 59():52-8. PubMed ID: 26299956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
